Molecular mechanisms of mesenchymal stem cell-based therapy in acute kidney injury

25Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Acute kidney injury (AKI) causes a lot of harm to human health but is treated by only supportive therapy in most cases. Recent evidence shows that mesenchymal stem cells (MSCs) benefit kidney regeneration through releasing paracrine factors and extracellular vesicles (EVs) to the recipient kidney cells and are considered to be promising cellular therapy for AKI. To develop more efficient, precise therapies for AKI, we review the therapeutic mechanism of MSCs and MSC-derived EVs in AKI and look for a better understanding of molecular signaling and cellular communication between donor MSCs and recipient kidney cells. We also review recent clinical trials of MSC-EVs in AKI. This review summarizes the molecular mechanisms of MSCs’ therapeutic effects on kidney regeneration, expecting to comprehensively facilitate future clinical application for treating AKI.

Cite

CITATION STYLE

APA

Lee, P. W., Wu, B. S., Yang, C. Y., & Lee, O. K. S. (2021, November 1). Molecular mechanisms of mesenchymal stem cell-based therapy in acute kidney injury. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms222111406

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free